alexa IL-25 Involved in Airway Inflammation of OVA-Induced Asthmatic Mice and the Inhibitory Effect of Glucocorticoid | OMICS International
ISSN: 2155-6121
Journal of Allergy & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

IL-25 Involved in Airway Inflammation of OVA-Induced Asthmatic Mice and the Inhibitory Effect of Glucocorticoid

Hong-Jia Li1, Fen Liu1, De-Gan Lu1, Ying-Hua Song1, Chao Wang1, Jin-Xiang Wu2, Ji-Ping Zhao2, Cai-Qing Zhang1* and Liang Dong2*

1Department of Pulmonary Disease, Qianfoshan Hospital, Shandong University, China

2Department of Pulmonary Diseases, Qilu Hospital of Shandong University, China

*Corresponding Authors:
Cai-qing Zhang
Department of Pulmonary Disease
Qianfoshan Hospital, Shandong University
NO.16766 by the 10 Run Road, Jinan
Shandong, 250014, China
E-mail: [email protected]
Liang Dong
Department of Pulmonary Diseases
Qilu Hospital of Shandong University
NO.44,Wenhua Xi Road, Jinan
Shandong, 250012, China
E-mail: [email protected]

Received date: July 27, 2013; Accepted date: September 15, 2013; Published date: September 20, 2013

Citation: Li HJ, Liu F, Lu DG, Song YH, Wang C, et al. (2013) IL-25 Involved in Airway Inflammation of OVA-Induced Asthmatic Mice and the Inhibitory Effect of Glucocorticoid. J Allergy Ther 4:151. doi:10.4172/2155-6121.1000151

Copyright: © 2013 Li HJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Allergy & Therapy

Keywords

Bronchial asthma; Airway inflammation; Interleukin-25; Glucocorticoid

Introduction

Allergic asthma is an inflammatory airway disease which is characterized by eosinophils and mast cells infiltration, goblet cell hyperplasia and airway hyperreactivity (AHR) [1]. IL-25 (IL-17E) is a member of IL-17 family and plays a critical role in inflammation and autoimmunity [2]. Recent studies have established that high level of IL-25 was associated with airway inflammatory disease in humans and mice [3] and could activate DCs to prime naive CD4+ T cells to differentiate into proinflammatory Th2 cells. To evaluate the role of IL- 25 in asthma, we generated the asthmatic mice model using OVA and identified the expression of IL-25 and Th2-type inflammatory cytokines in BALF in this process. We found that the expression of IL-25 mRNA and protein was significantly elevated in epithelial cells of mice with asthmatic inflammation, whereas treated with glucocorticoid decreased the eosinophils infiltration and IL-4, IL-5, and IL-13 in BALF [4]. This finding showed that IL-25 activated eosinophils to produce a range of asthmatic mediators and might play a pivotal role in maintaining Th2 central memory and sustaining asthmatic inflammation while glucocorticoid treatment was capable of inhibiting the procession.

Materials and Methods

Animals

Female BALB/c mice (n=30, weight 25 ± 5 g) were obtained from the Animal Centre of Shandong University, P. R. China. The mice were randomly divided into three groups—asthma group (n=10), control group (n=10) and glucocorticoid (GC)-treated group (n=10). All animal experiments undertaken in this study were done so with the approval of the Institutional Animal Care and Use Committee [5] of Shandong University.

Sensitization and provocation procedures

Mice in asthma group were injected intraperitoneally with 100 ug ovalbumin (OVA) in 1 mg aluminum hydroxide (Sigma) in a total volume of 0.25 ml of PBS twice at day 1 and 8, and then challenged with OVA aerosols (1% in PBS) for 30 min per day for 7 consecutive days. The control mice were sensitized and challenged with PBS instead. For the glucocorticoid-treated group, mice were inhaled budesonide suspension (0.5 mg/per mouse; R&D) 30 min before each challenged [6].

Airway responsiveness analysis

Expiratory resistance (Re) measurements of airway hyperresponsiveness (AHR) were made basally and in response to increasing doses of methacholine (Sigma-Aldrich). Methacholine was given over 5 min and the average Re value was measured 5 min after treatment.

Bronchoalveolar Lavage (BAL) and serum collected

We anesthetized the mice by an intraperitoneal injection of chloral hydrate (4 mg/g body weight) at 24 hours after the last challenge. Blood was collected by cardiac puncture and serum was stored at -70°C after centrifugation [7]. Brocho-alveolar lavage (BAL) was performed with PBS lavage six times (0.5 ml each time) through the cannulated trachea. A total of 2.5 ml BAL fluid was collected from every mouse [8]. The supernatant was decanted and stored at -80°C for further analysis.

Histology

Lungs tissues were excised completely from the chest cavity, and fixed with 10% neutral buffered formalin and then stained with hematoxylin and eosin (H&E) [9]. All images were developed at ×40.

Inflammatory cells count

We examined the cellular influx in the BALF by cell counting plate. The cell pellet was resuspended with PBS and washed twice and was subjected to count the number of eosinophils with Wright’s staining. All scoring and measurements were performed blinded by the same observer. Two hundred leukocytes were counted in each slide. Differential counts of cells were performed at ×400 (dry objective) using an Olympus microscope (Olympus). Cell types were identified based on morphologic criteria.

Cytokines in BALF and IgE in serum by ELISA

The levels of immunoglobulin (IgE) in serum and IL-25、IL-4 、IL-5、IL-13 and interferon (IFN)-γ in the BAL supernatants were examined accordingly by ELISA kits (R&D Systems) as described in the instructions. The kit is a solid phase phase sandwich enzyme linked immuno sorbent assay (ELISA). Samples were first pipetted into the wells. During the first incubation, the antigen and a biotinylated monoclonal antibody are simultaneously incubated. After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove the unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a colored reaction product. The intensity of this colored product is directly proportional to the concentration of inflammatory cytokines present in the samples.

Quantitative real-time PCR

Total RNA was isolated from mouse bronchus by the RNeasy Mini Kit (Qiagen, West Sussex, United Kingdom) and then reverse transcribed with random hexamers and AMV reverse transcriptase (Promega, Southampton, United Kingdom). cDNA was amplified by SYBR Green PCR Master Mix Reagent (Qiagen) in Rotor Gene 3000 (Corbett Research, Sydney, Australia). PCR conditions were 95°C 10 s, then 35 cycles of 95°C 5 s, 56°C 10s, 72°C 10 s. The quantity of IL-25 expression was assessed by the comparative Ct method. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.

Immunohistochemistry analysis

The sections were dewaxed, rehydrated and antigen retrieval was performed with 10 mM sodium citrate (pH 6.1). The slides were incubated with an anti-IL-25 antibody (Santa Cruz, USA) (l:25) overnight at 4°C and then processed with polyclonal rabbit anti-goat immunoglobulins/horseradish peroxidase (HRP) (1:100) for 30 min at 37°C. The nuclei were counterstained with hematoxylin. Control slides were incubated with normal Ig instead of a primary anti-body. IL-25- positive areas were quantified by densitometry using the image-pro plus software (Media Cybernetics, USA).

Statistical analysis

All the data were analyzed and computed by SPSS17.0 and demonstrated as mean ± standard deviation (SD). Both the level of cytokines and the quantity of IL-25 were analyzed by one-way analysis of variance. Person correlation analysis was performed to test the linear relationship between the quantitative variables. All test results were considered significant at p<0.05.

Results

Asthmatic model

This model was confirmed by detecting airway responsiveness, airway inflammation, serum levels of IgE and lung histopathology. As shown in Figure 1, the expiratory resistance of OVA-group mice was elevated, which indicated the marked airway hyperresponsiveness. The serum levels of IgE were increased dramatically in OVA-challenged mice relative to values in control group (Table 1). Histological analysis demonstrated an asthmatic phenotype with significantly increased airway eosinophil infiltration and goblet cell metaplasia (Figure 2). All these data indicate that we successfully generated the asthma mouse model by OVA.

allergy-therapy-Expiratory

Figure 1: Airway responsiveness in mice. Expiratory resistance was measured to assess airway responsiveness. Expiratory resistance was detectable in OVA model and in a methacholine dose–dependent manner.

allergy-therapy-Lung-histology

Figure 2: Lung histology. Sections of lung tissues were harvested 24 hours after last challenge, fixed with buffered formalin, and 5-μm sections were analyzed by HE staining. Original magnification,×40.

Group     N Total IgE (ng/ml) OVA-IgE (EU/ml)
Asthma    10 216 ± 31a 44 ± 5a
Control    10 29 ± 3 <10

Table 1: Concentration of total and OVA-specific IgE in serum.

Inflammatory cells

To determine the inflammatory response of mice, we examined the cellular influx in the BALF by cell counting plate (Figure 3). The number of total BALF cells was much higher in OVA group than in the control group. Mice exposed to OVA also demonstrated a significant increase in the number of eosinophils, neutrophils, lymphocytes and macrophages.

allergy-therapy-control-group

Figure 3: Quantify the number of cells in BALF. Values of cells represent the mean ± SD. *p<0.05 compared with control group, Δp<0.05 compared with OVA group.

Inflammatory cytokines

In the supernatants of BALF, we also detected much higher secretion of IL-4、IL-5, IL-13 as well as IL-25 with lower level of IFN-γ than the control group (Table 2). These results indicate that IL-25 worked in synergy with other Th2-type cytokines such as IL-4, IL-5 and IL- 13 to induce the recruitment of eosinophils in OVA induced asthmatic airway and thus promoted the Th2-type inflammatory responses in asthmatic airway inflammation.

Group N IFN-γ IL-4 IL-5 IL-13 IL-25
OVA 10 27.58 ± 3.40a 58.11 ± 8.09a 97.41 ± 11.04a 81.73 ± 8.25a 189.67 ± 18.15a
control 10 70.96 ± 2.08 20.30 ± 1.88 28.17 ± 4.11 26.53 ± 1.09 70.96 ± 14.31
GC 10 64.97 ± 4.51b 32.18 ± 6.12b 19.45 ± 2.03b 21.82 ± 3.51 76.39 ± 9.58b
F-value   116.12 231.04 85.04 79.87 103.08
P-value   <0.01 <0.01 <0.01 <0.01 <0.01

Table 2: The expression of IL-25, IL-4, IL-5, IL-13 and IFN-γ in BALF by ELISA ( x ± s, pg/ml).

IL-25 Expression in asthmatic mice

To identify the role of IL-25 in OVA-induced asthmatic mice, we detected the expression of IL-25 mRNA by quantitative real-time PCR and IL-25 protein by immunohistochemistry, respectively. The expression of IL-25 mRNA and protein on tracheal of mice exposed to OVA were significantly higher than that of mice in control group (Tables 3 and 4) (Figure 4). Tight Connection between the Expression of IL-25 and the Up-regulation of Cytokines

allergy-therapy-epithelial-cells

Figure 4: Expression of IL-25 in lungs. (A) IL-25 staining is up-regulated in airway epithelial cells and the inflammatory cells around the larger airways and blood vessels in asthma group while the control and the gucocorticoid (GC) treated group showed less staining. (B) Quantitation of IL-25. *p<0.05 compared with control group, Δp<0.05 compared with OVA group.

Group   N GAPDH –Ct
(Ct-G)
IL-25-Ct
(Ct-25)
2∆∆Ct
OVA 10 15.79 ± 0.81 16.03 ± 5.87a 1.48 ± 0.07a
control 10 14.02 ± 0.57 29.65 ± 0.74 0.74 ± 0.03
GC 10 14.21 ± 0.69 27.48 ± 1.28b 0.81 ± 0.06b
F-value   42.75 59.82 105.34
P-value   <0.01 <0.01 <0.01

Table 3: Quantitative detection of IL-25 mRNA in airway epithelium image.

Target GAPDH (131bp) IL-25 (192bp)
Forward 5'-AACAGGCGTCCCTTTCCGA-3' 5'-CAGCAAAGAGCAAGAACC-3'
Reverse 5'- GCCCAAGATGCCCTTCAGT-3' 5'-CCCTGTCCAACTCATAGC-3'

Table 4: Primers of GAPDH and IL-25 used in study.

To clarify the role of IL-25 on Th2-type cytokines, we performed a Person correlation analysis between IL-25 mRNA and IL-4, IL-5, IL-13 and IFN-γ in BALF. All the quantitative variables were showed normal distribution and we tested the linear relationship between IL-25 and the every other quantitative variable with Person correlation analysis. We found the expression of IL-25 mRNA was tightly positive correlated with the levels of IL-4 (r=0.748), IL-5 (r=0.691), and IL-13 (r=0.793) and negative correlated with the levels of IFN-γ (r=-0.574) (Figure 5). Thus Th2-type inflammation played a pivotal role in maintaining and sustaining asthmatic inflammation, and we presumed that IL-25 could activate eosinophils to produce such a range of asthmatic mediators and triggered the activation of Th2-type related cytokines network.

allergy-therapy-Tight-connection

Figure 5: Tight connection between the expression of IL-25 and IL-4, IL-5, IL-13 and IFN- γ in BALF. (rIL-4=0.748, rIL-5=0.691, rIL-13=0.793, rIFN-γ=-0.574, p﹤0.05).

Glucocorticoid inhibited cells infiltration and reduced cytokines level

We used inhaled budesonide during the challenge phase to determine the effect of glucocorticoid in the pathology of asthma. Inhaled budesonide resulted in the decrease of IL-25 mRNA in allergic mice; mice treated with inhaled budesonide showed a reduction in eosinophils infiltration in airway (Figure 2) as well as the levels of IL-25, IL-4, IL-5, and IL-13 in BALF (Figure 6). However there is no difference between the glucocorticoid treated group and the control group.

allergy-therapy-glucocorticoid

Figure 6: The effect of glucocorticoid treatment. (A) The levels of IL-25, IL-4, IL-5, IL-13 and IFN-γ in BALF; (B) IL-25 mRNA of lungs. *p<0.05 compared with control group, Δp<0.05 compared with OVA group.

Discussion

IL-25 was identified as being necessary for the up-regulation of the Th2 effecter cytokines and mirroring the role of Th1 response, such as asthma [1]. In this study, we showed that the expression of IL-25 was tightly positive correlated with the levels of IL-4, IL-5 and IL-13 and negative correlated with the levels of IFN-γ, which demonstrated that IL-25 was emerging as a key regulator of asthmatic inflammation because of its ability to promote Th2, while suppress Th1 cytokine responses. While T lymphocytes are responsible for driving allergenspecific type 2 responses, multiple reports have identified critical roles for innate immune responses. First, IL-25 could activate CD4+ T cells to produce chemokines and exacerbate asthmatic inflammation. Besides, IL-25 could induce eosinophils, IL-4, IL-5 secretion and lead to airway hyperresponsiveness and inflammatory response. Therefore, IL-25 acted as the bridge between the innate and the adaptive immune responses in allergic asthma needs our further investigation [2]. Besides, there are also controversial reports regarding the cell types that produce IL-25. For example, Fort et al. [10] showed that IL-25 was expressed exclusively by Th2 cells, whereas Wang et al. [4] demonstrated that eosinophils and basophils, but not other immune cells (T cells, B cells, monocytes, dendritic cells, etc.), secreted IL-25. Our immunohistochemistry analysis showed that IL-25 was highly expressed in epithelial cells of the airway in mice with asthma, which was consistent with the research of Klein et al. [11]. We also demonstrated that in the lungs of mice with asthma, the expression of IL-25mRNA and protein is increased in the airway epithelium. These results confirm that IL-25 is markedly over expressed in the lungs of mice sensitized and challenged with OVA [10,12].

Glucocorticoid treatment had long been considered to be the way to decrease asthmatic inflammation [13]. When the asthmatic animals were given inhaled budesonide treatment, this airway inflammation could also be inhibited by the decrease of inflammatory cells and cytokines infiltration [14]. In our study, animals receiving budesonide inhalation showed a significant decrease in total and classified cells as well as Th2 cytokines levels (IL-4, IL-5, and IL-13) in BALF. Although our data supported IL-25 acting with other Th2 cytokines in asthmatic inflammation, mice deficient in IL-4, IL-5, and IL-13 could also induced AHR with IL-25 administration, which showed independently of the classic Th2 inflammatory reposes. Besides, current clinical studies have found that some asthmatic patients were resistant to glucocorticoid treatment even with high dose and the animal studies also showed that steroid resistant Th17 cells might explain neutrophilmediated asthmatic inflammation [15]. Since IL-25 is one of the IL- 17 family members, IL-25 signaling pathway might provide a novel target for steroid-resistant asthmatic therapy, which needs our further research into mechanisms underlying asthma’s pathophysiology [16]. Further investigation will also be required to determine whether IL- 25 acts through the induction of known broncho-constrictors such as the leukotrienes, or via molecules such as the recently described acidic chitinase [17].

Conclusion

The expression of IL-25 was increased in airway of asthma as well as other Th2-related cytokines secretion [18]; while budesonide inhalation could reduce type 2 cytokine induced inflammation and prevent airway hyperresponsiveness [19]. It is noteworthy that IL-25 might provide a novel target in the glucocorticoid therapeutic intervention of asthmatic inflammation.

Acknowledgement

The authors gratefully thank Dr. Rutao Cui for supplying IL-25 antibody. This work was finished in Key Laboratory of Cardiovascular Remodeling and Function Research of Chinese Ministry of Education and Public Health, Shandong University Qilu Hospital and medical research center of Shandong University Qianfoshan Hospital. This work was supported by the Natural and Science Foundation of Shandong Province (ZR2011HM020), The National Natural Science Foundation of China (81270072) and The Science and Technology Foundation of Shandong Province (2012GGB14068).

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11669
  • [From(publication date):
    October-2013 - Dec 14, 2017]
  • Breakdown by view type
  • HTML page views : 7901
  • PDF downloads : 3768
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version